Journalists

Journalists

Covering current events in science, the environment, technology and health requires a context and reliable sources that respond quickly.

¿Qué me ofrece?

When science hits the headlines, we publish reactions, explanations, and in-depth analysis from reliable sources, capturing both the evidence and the debates. Our library of science journalism resources and the briefings may be of use to you. Consult our directory of research centres.

Icono
Cómo trabajamos

We are on the lookout for any controversial information about science (embargoed or not), in order to react with the agility the media needs. Sign up to receive our embargoed contents, all under the Creative Commons licence. Find out more about how we work here.

Título qué me ofrece
What we offer you
Título cómo trabajamos
How we work

Climate change and an ageing population will accentuate disparities in heat and cold deaths in Europe

A modelling study published in The Lancet Public Health using data from 854 European cities estimates that heat-related deaths will triple in Europe by 2100 under current climate policies. A slight decrease in cold-related deaths is projected, while heat-related deaths will increase in all parts of Europe. The most affected areas will include Spain, Italy, Greece and parts of France. Currently, around eight times as many people in Europe die from cold as from heat, but this proportion is projected to decrease considerably by the end of the century.

0

Study reviews adverse reaction reports for semaglutide and suicide

In research using a WHO database of adverse drug reactions, the authors identified a signal of disproportionality of suicidal ideation with semaglutide, one of the drugs used to treat type 2 diabetes and obesity. The study, published in JAMA Network Open, did not find this signal for liraglutide, another drug indicated for these treatments.

0

The EU considers the risk of mpox spreading to the general population ‘low’ and does not rule out more imported cases

With the increase in cases of mpox, the European Union's Health Security Committee met on Monday. According to the Ministry of Health, the meeting concluded ‘with recommendations very similar to those previously issued by the WHO and the ECDC’. The risk of the likelihood of mpox spreading to the general EU population is currently considered to be ‘low’, although it increases in populations with close contact with diagnosed cases and in particularly vulnerable people. Further imported cases in the EU are not excluded and vaccination of the general population is not recommended. In addition, the HSC does not recommend border control.  
 

0

New variant of mpox confirmed in Sweden

Sweden's public health agency issued a statement on Thursday indicating that a person has been diagnosed with mpox - formerly called monkeypox - caused by variant clade I. According to the Swedish agency, this is the first case of this variant to be diagnosed outside the African continent. The person would have been infected during a stay in a part of Africa where there is an outbreak of this variant of mpox, according to the statement. The announcement comes a day after the World Health Organisation declared the mpox outbreak a public health emergency of international concern.

0

One in four people with brain-damage who do not respond to stimuli may have some degree of consciousness

An international team of researchers has studied 241 brain-damaged people apparently unable to respond to external stimuli. Using techniques such as functional magnetic resonance imaging and electroencephalogram, they have detected signs of brain activity in 25 % of them that, according to the authors, ‘suggest that they may be interacting with the outside world’. The results are published in the journal NEJM

0

Keto diet improves results of pancreatic cancer drug in mice

A ketogenic diet improves the results of a pancreatic cancer therapy in mice, according to a study published in Nature. The US research team fed the animals a high-fat, low-carbohydrate diet before administering them a new drug, currently in clinical trials; in the absence of glucose, the body converts fat into ketone bodies. The drug blocks the metabolism of fat - the cancer's only source of energy while the mice are on this diet - and slows the growth of pancreatic tumours. 

0